As an early stage biotech devoted to developing psychedelic medicines, Mind Medicine (NASDAQ: MNMD) is a risk lover's paradise encapsulated into a stock. The company won't have any therapies on the market for quite some time, assuming it can ever successfully develop them at all. Buying shares is so risky and speculative that it's similar to buying a lottery ticket -- and that's why it could be a candidate to become a meme stock.

In fact, there are several reasons why Mind Medicine has a shot at becoming a meme-driven roller-coaster ride any day now. If you already have an adequately diversified portfolio and are willing to consider a meme stock -- with all the oversized risks that may entail -- read on.

Mind Medicine just received a nod of approval from one of 2022's ascendant meme stock investors. Jake Freeman is a 20-year-old investor known for making a shocking sum of around $110 million on his recent trade of Bed Bath & Beyond.

Continue reading

Source Fool.com